Company intelligence / Profile preview

Transverse Industries

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Transverse is a biotechnology company focused on developing novel therapeutics for neurodegenerative disorders, with a specific emphasis on lysosomal biology. The company's lead programs target the GBA1 pathway to address the underlying pathology of Parkinson's disease and Gaucher disease. By developing small molecule activators of glucocerebrosidase, Transverse seeks to restore lysosomal function and improve cellular health in affected neurons. The company is supported by leading venture capital firms and is advancing its pipeline through pre-clinical development.

Therapeutic areas: NeurologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Transverse Industries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transverse Industries.

Explore the full profile